Utah has become the first state in the nation to allow artificial intelligence to renew certain medical prescriptions without any direct involvement from a doctor. The move marks a major milestone for both health care automation and medical regulation in the United States, and it raises serious questions about safety, oversight, and how much responsibility patients and regulators are willing to hand over to software.
The pilot program, launched quietly last month, allows an AI system developed by health tech startup Doctronic to handle prescription renewals for patients with chronic conditions. Instead of scheduling an appointment or messaging a physician, patients interact directly with an automated system that reviews their history, asks medical screening questions, and sends approved refills straight to pharmacies.
State officials say the goal is to cut costs, reduce treatment delays, and improve access to routine care. Critics argue the program moves too quickly into sensitive medical decisions that have traditionally required human judgment.
Either way, Utah is now serving as a national test case for how far AI can go in clinical decision making.
How the Utah AI Prescription Program Works
Patients using the system first verify they are physically located in Utah through a web based portal. Once verified, the AI accesses the patient’s prescription history and identifies which medications are eligible for automated renewal.
The system then walks patients through the same clinical screening questions a physician would typically ask before approving a refill. These questions cover symptoms, side effects, changes in condition, and other warning signs that could suggest a medication adjustment or medical follow up is needed.
If the AI determines that renewal is appropriate, it sends the prescription directly to the patient’s pharmacy without any human review.
The pilot is limited to about 190 commonly prescribed medications used to manage chronic conditions. Drugs related to pain management, ADHD, injectable medications, and higher risk therapies are excluded from the program for safety reasons.
Doctronic co founder and co CEO Matt Pavelle said the system is designed to help people avoid dangerous gaps in treatment.
“It’s hard to get a renewal. If you have a chronic condition and you can’t get your medication, terrible things happen.”
The company currently charges $4 per refill, though Pavelle said that price is temporary and could drop as volume increases. Longer term, the company expects renewals to be covered by insurance or bundled into low cost subscription models.
Why Utah Approved It
Utah officials say the pilot is about more than convenience. It is part of a broader strategy to test how AI can relieve pressure on an overburdened health care system.
Health care costs continue to rise, and many rural communities struggle with limited access to providers. State leaders believe automating routine prescription renewals can free doctors to focus on more complex cases.
Margaret Busse, executive director of the Utah Department of Commerce, said the program also reflects a desire to encourage innovation while staying within state regulatory authority.
“It’s also a way to provide a pathway to innovation for entrepreneurs who are using AI in creative ways that may be bumping up against regulation,” she said.
At the state level, regulators typically oversee how medicine is practiced, while the federal government oversees medical devices and pharmaceuticals. Utah is treating Doctronic’s system primarily as a medical practice issue rather than a medical device issue, allowing it to operate under state oversight for now.
That decision could change if federal regulators step in.
Doctors Warn of Safety and Ethical Risks
Physician groups have raised concerns about removing doctors from any part of prescribing, even when limited to renewals.
Dr. John Whyte, CEO and executive vice president of the American Medical Association, issued a cautionary statement about relying on AI without physician involvement.
“While AI has limitless opportunity to transform medicine for the better, without physician input it also poses serious risks to patients and physicians alike.”
Doctors point to several potential dangers:
- Missing subtle symptoms that signal worsening conditions
- Overlooking drug interactions across multiple medications
- Patients attempting to manipulate automated systems
- Difficulty addressing mental health or addiction related risks
Addiction specialists in particular worry about automated pathways being targeted by individuals seeking inappropriate access to medications, even when high risk drugs are excluded from the system.
Busse acknowledged that trust is central to the program’s success.
“The company has to do that kind of trust building with their patients. We want it to be done in such a way that people will trust that Utah is looking at this carefully and is not being cavalier about how we granted this regulatory mitigation. In a way it’s a risk for us as we do this.”
Doctronic Says Its AI Outperforms Human Clinicians
Doctronic argues that its system is not only safe but statistically more consistent than human decision making in routine cases.
The company shared internal data with Utah regulators comparing AI recommendations with physicians across 500 urgent care cases. According to Doctronic, treatment decisions matched physicians 99.2 percent of the time.
“The AI is actually better than doctors at doing this,” said Dr. Adam Oskowitz, Doctronic co founder and an associate professor of surgery at the University of California San Francisco. “When you go see a doctor, it’s not going to do all the checks that the AI is doing.”
Oskowitz said the system is programmed to escalate cases to physicians whenever there is uncertainty or unusual risk. For each medication category, the first 250 renewals must be reviewed by human doctors to validate performance before the AI can operate autonomously in that class.
The company has also obtained a malpractice insurance policy specifically covering AI driven medical decisions. That means the system carries legal and financial responsibility similar to a physician.
“In medicine, there’s always going to be potential issues that patients have,” said Oskowitz. “Whether it’s caused by the AI or not, we will take the risk. I think this is going to be infinitely safer than a human doctor.”
Where the FDA Fits In and Why It Matters
The Food and Drug Administration has not yet weighed in publicly on Utah’s program.
That silence is significant because it highlights a gray area in how AI medical systems are regulated in the United States.
Traditionally, states regulate medical practice while the FDA regulates medical devices. But AI systems that make clinical decisions blur that line.
Lowell Schiller, former chief counsel for the FDA, said Doctronic’s AI could fall under federal oversight if it is considered a device used to diagnose, treat, or prevent disease.
At the same time, Schiller noted that the FDA sometimes defers to state authority in areas where enforcement would conflict with state law, citing medical marijuana as an example.
If the FDA ultimately decides Doctronic is operating without proper authorization, it could require the company to submit its system for formal review. That process can take months or even years, depending on how risky regulators judge the technology to be.
Under President Donald Trump, the FDA has shown willingness to challenge new health technologies that operate without approval. Earlier this year, the agency warned health wearable company Whoop that it could not market blood pressure estimation features without authorization.
The FDA typically aims to review lower risk devices within about 150 days, but approval timelines can extend much longer when new technologies lack direct regulatory precedents.
For now, the agency has declined to comment, saying the issue falls outside its current regulatory purview.
Zach Boyd, director of Utah’s artificial intelligence policy office, said the state is focused on regulating medical practice while federal agencies determine their own role.
“Now we’re in this weird place where there are devices, maybe you could call them devices, that are purporting to practice medicine,” said Boyd. “Our philosophy has been to just take care of our side of the state’s authority and the FDA is going to figure out what it’s going to figure out.”
Why This Matters for the Health Care Industry
Even if Utah’s program remains small, it could set a precedent that reshapes how routine medical services are delivered.
Prescription renewals account for a massive volume of primary care interactions. Automating that workload could reduce staffing pressure, shorten appointment backlogs, and lower administrative costs across clinics and pharmacies.
Health systems are already using AI to assist with radiology, pathology, medical coding, and patient triage. Prescription renewal is one of the first areas where AI is now directly replacing physician decisions rather than simply assisting them.
If the Utah model proves safe and effective, insurers and hospital systems may push for similar automation to control rising labor costs.
From a business standpoint, this opens major opportunities for health AI startups, pharmacy benefit managers, and telehealth platforms that integrate automated prescribing workflows.
It also raises difficult labor questions about how many medical roles could eventually be partially automated, especially in primary care.
What It Means for Investors
The Utah pilot is small, but its implications extend into multiple fast growing investment sectors:
- Health care artificial intelligence
- Digital therapeutics
- Telehealth platforms
- Pharmacy automation
- Regulatory technology
Investors are already pouring billions into AI driven health solutions, but regulatory uncertainty has slowed some commercial rollouts. A successful real world deployment of AI prescribing could reduce perceived regulatory risk across the sector.
Publicly traded companies that could benefit include telehealth providers expanding AI triage tools, pharmacy chains investing in automation, and cloud platforms that supply health compliant AI infrastructure.
At the same time, regulatory backlash could slow adoption if federal agencies tighten oversight.
For investors, the takeaway is not that AI will instantly replace doctors, but that health systems are now actively testing where automation can replace human judgment in limited contexts.
That trend is unlikely to reverse, especially as labor shortages persist and cost pressures intensify.
Medicine Is Entering Its Automation Phase
The Utah pilot reflects a broader reality that medicine is entering an era where algorithms increasingly perform tasks once reserved for highly trained professionals.
From diagnostic imaging to scheduling to prescription renewals, software is steadily absorbing administrative and clinical decision making functions.
Supporters argue this will improve access and reduce costs. Critics warn it risks depersonalizing care and introducing new types of systemic errors.
What is clear is that AI is no longer just a behind the scenes assistant in medicine. In Utah, it is now a frontline decision maker.
Whether that model spreads nationally will depend less on technology and more on trust, regulation, and how much responsibility society is willing to assign to machines when health and safety are on the line.
About Author
